Blueprint Medicines Q2 2023 Earnings Report
Key Takeaways
Blueprint Medicines reported second quarter 2023 financial results, achieving $39.9 million in AYVAKIT/AYVAKYT net product revenues and $57.6 million in total revenues. The FDA approved AYVAKIT for adults with indolent systemic mastocytosis on May 22, 2023. The company also announced development candidate BLU-808 for treating mast cell disorders.
Achieved $39.9 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in Q2 2023.
Total revenues reached $57.6 million in Q2 2023.
AYVAKIT was approved by the FDA for treating adults with indolent systemic mastocytosis on May 22, 2023.
Announced development candidate BLU-808 for treating patients with mast cell disorders, including chronic urticaria.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Blueprint Medicines plans to achieve milestones by the end of 2023.